Core Viewpoint - The company, Yuekang Pharmaceutical, reported a decline in revenue for 2024, with total revenue of 3.781 billion yuan, a year-on-year decrease of 9.90% [1] Group 1: Operating Performance - The revenue breakdown shows that cardiovascular and anti-infection products generated 2.105 billion yuan and 789 million yuan, respectively, with declines of 20.73% and 22.67% [1][4] - The gross profit margin for the company was 58.76%, with significant differences among product categories; anti-infection products had a gross margin of 6.91%, while cardiovascular products had a margin of 91.08% [1][4] - The company provided a detailed table of sales revenue, volume, unit price, and year-on-year changes for different product types [2][3] Group 2: Revenue Analysis - The decline in cardiovascular product revenue was primarily due to a drop in sales of Ginkgo biloba extract injection, which saw an 8.47% decrease in volume and a reduction in average selling price [5] - The anti-infection product revenue decline was attributed to a shrinking market demand and increased competition, leading to lower sales volumes [5] - Conversely, the digestive system product revenue increased by 123.04% due to improved sales of omeprazole enteric-coated capsules, driven by enhanced marketing strategies [5] Group 3: Gross Margin Analysis - The gross margin differences among product types were influenced by drug classification and centralized procurement impacts [6][7] - Cardiovascular products maintained high margins due to effective market development and production cost management, while anti-infection products faced lower margins due to competitive pricing pressures [7] - The company’s gross margins were compared with industry peers, showing that its margins were generally in line with industry averages [8] Group 4: Sales and Marketing Expenses - The company reported a decrease in marketing and promotion expenses from 1.715 billion yuan in 2023 to 1.242 billion yuan in 2024, a reduction of 27.59% [10][11] - The decrease was attributed to the expansion of centralized procurement, which stabilized sales volumes in public medical institutions, leading to reduced promotional activities [11] - The company’s pricing strategy for major products considered various factors, including R&D costs, market demand, and competition [12] Group 5: Related Party Transactions - The company increased its purchases from Anhui Hengshun Information Technology Co., Ltd. to 221.678 million yuan in 2024, a significant increase from the previous year [18][20] - Anhui Hengshun primarily engages in the production and sale of various pharmaceutical intermediates, and the increase in purchases was due to expanded sales channels and cost advantages [19][20] - The procurement prices from Anhui Hengshun were found to be fair and competitive compared to other suppliers [21]

主因产品原血白蛋白原产国瑞典奥地利德国和法国适用于低血溶量及低血溶量性休克力强高的颅内压水肿及腹血防止及治愈低蛋白血症及新生儿高胆红血红素血症注射用淘宝福星钠安可鑫原产国为塞浦路斯 好的各位投资人大家早上好下面由我为大家介绍一下公司的基本情况星科荣耀控股于2016年成立于在香港主板上市公司现在分为生物医药 医验美学及供应链平台三大业务板块2011年四川星科荣耀与成立获安可心麦道币中国的独家行销权 在12年获奥克特法马与中国24个省份的独家授权公司在2014年在四川成都双流保税区新建了链设施12年在香港主板上市公司在1920年分别获得奥地利德国及瑞典产人血白蛋白的全国独家授权21年集团确定建立的医美业务板块启动了具体内置PCL加X的产品性研发 22年公司获法国产人士白蛋白的独家授权同年新克隆医美产一员落户成都天府国际生物城并收购德杨德美医疗美容医院23年成都恒美盛生物科9000公司在少米针平华针等项目研究工作中强势推进24年新克隆国际生物医药供应链服务中心项目二期开工同年海口新克隆基地项目开工仪式顺利举行 以报告今年本集团收益增加11.1%或人民币2.81亿元至人民币28.21亿其中人血白蛋白注射液销售收入增加 ...